Zenas BioPharma
ZBIO
28.18
+1.24
+4.60%
Zenas BioPharma
US · ZBIO
#2856 by market cap
Listed 2024
28.18
+1.24
+4.60%
Live - 5344 symbols - heartbeat 503s ago
· 2026-10-08 07:09
Pre-market
28.26
+0.28%
After-hours
28.18
0.00%
- Market cap
- 1.84B
- P/E (TTM)i
- -2.93
- P/Bi
- 7.43
- EPSi
- -8.44
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on ZBIO?
Anonymous reader poll. Unscientific, not investment advice.
Recent news
-
Rating change
Analysts Offer Insights on Healthcare Companies: Zenas BioPharma, Inc. (ZBIO) and Atai Beckley N.V. (ATAI)TipRanks · 2026/6/27
-
Rating change
Analysts' Top Healthcare Picks: Zenas BioPharma, Inc. (ZBIO), Entrada Therapeutics Inc (TRDA)TipRanks · 2026/6/3
-
Rating change
Analysts Are Bullish on Top Healthcare Stocks: Alpha Cognition Inc (ACOG), Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/6/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: MDxHealth (MDXH), Opko Health (OPK) and Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Rating change
Wedbush Initiates Zenas BioPharma(ZBIO.US) With Buy Rating, Announces Target Price $45Market Newswire · 2026/5/14
-
Rating change
Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/5/14
-
Rating change
Zenas BioPharma, Inc. (ZBIO) Receives a Buy From GuggenheimTipRanks · 2026/8/14
-
Rating change
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55Market Newswire · 2026/8/14
-
Rating change
Morgan Stanley Maintains Zenas BioPharma(ZBIO.US) With Hold Rating, Raises Target Price to $32Market Newswire · 2026/8/17
-
Rating change
Wedbush Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Rating change
Citi Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/11
-
Wedbush Remains a Buy on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/30
-
Rating change
Morgan Stanley Reaffirms Their Hold Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/8/14
-
Rating change
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/9/11
-
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44Market Newswire · 2026/9/30
-
Rating change
H.C. Wainwright Keeps Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/22
-
Rating change
Wedbush Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $45Market Newswire · 2026/8/14
-
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $48Market Newswire · 2026/10/2
-
Analysts Are Bullish on Top Healthcare Stocks: DocGo (DCGO), Zenas BioPharma, Inc. (ZBIO)TipRanks · 2026/9/30
-
Citi Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Raises Target Price to $48Market Newswire · 2026/9/30
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-10-08 07:09:11 · For reference only, not investment advice and not tailored to your situation.